# Science Corporation

> CE-marked PRIMA retinal implant and wearable glasses for limited functional central-vision restoration, plus experimental biohybrid neural interfaces.

## Why it is interesting

Science announced a $400M Series D after EU PRIMA commercialization authorization, while its reported $3.5B valuation and US regulatory prospects remain distinct from documented sales and clinical use.

## Profile

- **Latest funding:** Series D announced — $400M (November 17, 2026)
- **Latest known valuation:** $3.5B reported by TechCrunch citing unnamed source; pre/post-money basis unspecified (November 17, 2026)
- **Total disclosed equity funding:** $630M
- **Stage:** other
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-18T00:00:00.000Z
- **Latest funding investors:** Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, PLC Neurotech

## Key facts

- $400M Series D is new financing; >$900M historical lifetime capital reported by the company is not another round.
- $3.5B valuation is journalist-reported, not issuer-confirmed, and its pre/post-money basis was not verified.
- PRIMA has EU CE marking; US HUD designation is not FDA marketing approval.

## Funding history

- Series D announced · $400M · November 17, 2026
  Source: https://science.xyz/news/series-d/
- Series C · $230M · March 5, 2026
  Source: https://science.xyz/news/series-c/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 18, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/science-corporation-prima-retinal-implant
